Number of qualified patients: CDEC talked about the uncertainty in the quantity of sufferers with moderately extreme to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical authorities consulted by CADTH indicated that some sufferers who're classified as having mild or average ailment could have a extreme bleeding phenotype, https://hemgenix50471.educationalimpactblog.com/57401933/about-hemgenix